PROLONGED SUPPRESSIVE ANTIBIOTIC THFRAPY FOR PROSTHETIC JOINT INFECTION IN



Virginie Prendki, Thibaut Fraisse, Emmanuel Forestier, Véronique Trombert, Aurélien Dinh, Gaëtan Gavazzi for The French Study Group on Suppressive Antibiotic Therapy in Prosthetic Joint Infection

Introduction

Definition of Prolonged Suppressive Antibiotic Therapy (PSAT): an antibiotic therapy prescribed as a long-life treatment. Data about it are scarce

Our objective: to describe its characteristics and outcomes in whether prosthetic joint infections (PJI) in elderly patients.

Methods

-French national retrospective multicentric study.

-Analysis of epidemiological characteristics, drug indication, tolerance, outcomes of a cohort of patients 75 years old and treated with PSAT for PJI.

-Event or failure: withdrawal of PSAT and/or systemic progression of infection under PSAT and/or death.

-A composite binary outcome defined as the first occuring event among these 3 previous type of events was used.

Results

-27 centres: infectious diseases (69, 50.7%), orthopaedics (32, 23.5%), geriatrics (18, 13.2%) and internal medicine (17, 12.5%) units.

-136 patients, median age: 84 years {IQR 79-89}. 132 with identified pathogen.

-Initial intravenous (IV) antibiotic therapy prescribed for 95 patients.

-PSAT prescribed as immediate palliative in 30.1% of cases: betalactam, cotrimoxazole, fluoroquinolone.

-First-line PSAT stopped in 45 patients (33.1%).

-24 patients died (17.6%); 2 were infection-related (8.3%).

-The median follow-up of patients: 16 months (range 0-112).

-The 2-year survival rate without event was 70% (95% confidence interval [CI], 62.5%-77.5%).

-Increased risk of an event in case of: monomicrobial infection (HR=9.15, P=0.041), Mac Cabe score equal to 3 (HR=2.47, P=0.054), PSAT given by another person (HR=3.39, P=0.006), bactaeremia (HR=2.73, P=0.032) (Stepwise backward regression).

-Initial IV antibiotic therapy associated with a decreased risk of treatment failure (HR=0.43, P=0.006).

Key conclusions

-Life-long antibiotic therapy might postpone treatment failure and may be beneficial in selected cases, in older patients with limited life expectancy in whom surgery is limb or life-threatening.

-IV therapy may partially reduce the inoculum size, facilitating the efficacy of oral PSAT.

-Large prospective multicentric studies, including comprehensive geriatric assessment, are needed to confirm the place, efficacy and safety of PSAT in PJI and to homogenize medical practice.


Virginie.prendki@gmail.com


Hôpitaux Universitaires


Genève

Rouch Paris Strashourg Rennes Col Bello Nantes Chalon sur Saðne Limoges Brive La Gaillarde Aix le Grenoble Alès Avignor











Madel



EUGMS Congress, Lisbon 2016 ID 3971